Immix Biopharma annual depreciation and amortization
2020
2021
2022
2023
2024
2025
Immix Biopharma Depreciation & Amortization Growth & History (IMMX)
Immix Biopharma's depreciation and amortization was $364,501 for fiscal 2025.
View full Immix Biopharma company overviewImmix Biopharma annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $364,501 | $249,113 | +215.89% |
| 2024 | 2024-12-31 | $115,388 | $109,920 | +2010.24% |
| 2023 | 2023-12-31 | $5,468 | $3,333 | +156.11% |
| 2022 | 2022-12-31 | $2,135 | −$333 | −13.49% |
| 2021 | 2021-12-31 | $2,468 | $147 | +6.33% |
| 2020 | 2020-12-31 | $2,321 | — | — |
Immix Biopharma quarterly depreciation and amortization
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $130,884 | $51,049 | +63.94% |
| Q1 2026 | 2026-03-31 | $130,766 | $71,586 | +120.96% |
| Q4 2025 | 2025-12-31 | $90,631 | — | — |
| Q3 2025 | 2025-09-30 | $134,855 | $108,949 | +420.56% |
| Q2 2025 | 2025-06-30 | $79,835 | $55,540 | +228.61% |
| Q1 2025 | 2025-03-31 | $59,180 | $35,330 | +148.13% |
| Q3 2024 | 2024-09-30 | $25,906 | $24,525 | +1775.89% |
| Q2 2024 | 2024-06-30 | $24,295 | $23,789 | +4701.38% |
| Q1 2024 | 2024-03-31 | $23,850 | $23,345 | +4622.77% |
| Q3 2023 | 2023-09-30 | $1,381 | $815 | +143.99% |
| Q2 2023 | 2023-06-30 | $506 | $123 | +32.11% |
| Q1 2023 | 2023-03-31 | $505 | −$115 | −18.55% |
| Q3 2022 | 2022-09-30 | $566 | −$54 | −8.71% |
| Q2 2022 | 2022-06-30 | $383 | −$237 | −38.23% |
| Q1 2022 | 2022-03-31 | $620 | $12 | +1.97% |
| Q3 2021 | 2021-09-30 | $620 | — | — |
| Q2 2021 | 2021-06-30 | $620 | — | — |
| Q1 2021 | 2021-03-31 | $608 | — | — |
Immix Biopharma depreciation and amortization trends
Over the last five fiscal years, Immix Biopharma's depreciation and amortization increased from $2,321 to $364,501, a change of $362,180. The latest reported quarter, Q2 2026, shows $130,884.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Immix Biopharma source filings ↗